Core Points - The company, Xingqi Eye Medicine, announced that it has received the drug registration certificate for Oubukain Hydrochloride Eye Drops from the National Medical Products Administration [2] Group 1 - The approval of the drug registration certificate is a significant milestone for the company, indicating regulatory compliance and potential market entry [2] - The product, Oubukain Hydrochloride Eye Drops, is expected to enhance the company's product portfolio and may lead to increased revenue opportunities [2]

Core Viewpoint - The company has received approval from the National Medical Products Administration for the drug registration certificate of Oubakain Hydrochloride Eye Drops, indicating a significant advancement in its product offerings in the ophthalmic field [1] Group 1: Product Approval - The approved product is Oubakain Hydrochloride Eye Drops, which contains Oubakain Hydrochloride as the active ingredient [1] - This eye drop formulation is a single-dose product that does not contain any preservatives [1] - The indication for this product is for surface anesthesia in the field of ophthalmology [1]

Core Viewpoint - The company has received approval from the National Medical Products Administration for its drug, Oubakain Hydrochloride Eye Drops, which is intended for surface anesthesia in ophthalmology [1] Company Summary - The approved product is a single-dose formulation that does not contain preservatives [1] - The active ingredient in the eye drops is Oubakain Hydrochloride [1] - This approval marks a significant milestone for the company in expanding its product offerings in the ophthalmic field [1]

Core Viewpoint - The company Shapuaisi (603168.SH) has received the drug registration certificate for Oubukain Hydrochloride Eye Drops from the National Medical Products Administration, indicating a significant advancement in its product offerings in the ophthalmology field [1] Group 1 - The approved Oubukain Hydrochloride Eye Drops are intended for surface anesthesia in ophthalmology [1]

Core Viewpoint - The company, Shapuaisi (603168.SH), has received the drug registration certificate for Oubukain Hydrochloride Eye Drops from the National Medical Products Administration, indicating a significant advancement in its product offerings in the ophthalmology field [1] Group 1 - The approved Oubukain Hydrochloride Eye Drops are intended for surface anesthesia in ophthalmology [1]

Core Viewpoint - The company received the drug registration certificate for Oubkain Hydrochloride Eye Drops from the National Medical Products Administration, indicating a significant regulatory approval for a product used in ophthalmic surface anesthesia [1] Company Summary - Shapais (603168) announced on October 24 that it has obtained the drug registration certificate for Oubkain Hydrochloride Eye Drops [1] - The eye drops are intended for use in the field of ophthalmology, specifically for surface anesthesia [1]